Biology and therapy of mantle cell lymphoma

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current Opinion in Oncology

• Publication date

  2005-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/01.cco.0000174039.69656.2bPMID 16093790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hematopoietic stem-cell transplantation in mantle-cell lymphoma

  2005cited by this paper
• Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

  2005cited by this paper
• Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.

  2005cited by this paper
• Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

  2005cited by this paper
• Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2005cited by this paper
• Proteomic analysis of mantle-cell lymphoma by protein microarray.

  2005cited by this paper
• Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM

  2005cited by this paper
• Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa

  2005cited by this paper
• Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes.

  2004cited by this paper
• Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs

  2004cited by this paper
• The Leukemic Presentation of Mantle-cell Lymphoma: Disease Features and Prognostic Factors in 58 Patients

  2004cited by this paper
• Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.

  2004cited by this paper
• Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events.

  2004cited by this paper
• Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

  2004cited by this paper
• Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions.

  2004cited by this paper
• High Incidence of Unbalanced Chromosomal Changes in Mantle Cell Lymphoma Detected by Comparative Genomic Hybridization

  2004cited by this paper
• Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research

  2004cited by this paper
• Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)

  2004cited by this paper
• Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.

  2004cited by this paper
• Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.

  2004cited by this paper
• Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.

  2004cited by this paper
• Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.

  2004cited by this paper
• Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.

  2004cited by this paper
• Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis.

  2004cited by this paper
• Molecular basis of mantle cell lymphoma

  2004cited by this paper
• An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma

  2004cited by this paper
• Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.

  2003cited by this paper
• Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

  2003cited by this paper
• Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

  2002cited by this paper
• From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades.

  2002cited by this paper
• Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

  2000cited by this paper
• Mantle cell lymphoma

  2000cited by this paper

• Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study

  2021cites this paper
• Bortezomib in combination with fludarabine and cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study

  2019cites this paper
• Molecular Basis of Primary Hyperparathyroidism

  2015cites this paper
• Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma

  2015cites this paper
• Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.

  2015cites this paper
• A rare case of leukemic presentation of blastoid variant of mantle cell lymphoma with isolated splenic involvement: Flowcytometric revelation.

  2015cites this paper
• Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.

  2014cites this paper
• NKT Cell Responses to B Cell Lymphoma

  2014cites this paper
• Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

  2013cites this paper
• The role of the ubiquitin proteasome system in lymphoma.

  2013cites this paper
• Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach

  2013cites this paper
• lymphoma Development of a murine model for blastoid variant mantle-cell

  2013cites this paper
• Novel targeted therapies for mantle cell lymphoma

  2012cites this paper
• Primary mantle cell lymphoma of gastrointestinal tract - a case report

  2012cites this paper
• Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles.

  2012cites this paper
• PRIMARNI MANTLE CELL LIMFOM GASTROINTESTINALNOG TRAKTAPRIKAZ BOLESNIKA

  2012cites this paper
• London Cancer New Drugs Group APC / DTC Briefing Rituximab for Mantle Cell Lymphoma g May 2011

  2011cites this paper
• Mantle cell lymphoma, blastoid variant presenting as acute leukemia - a rare case report.

  2011cites this paper
• Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma

  2011cites this paper
• Characterisation of the voltage gated proton channel HVCN1 in B cells

  2011cites this paper
• Combination anti-CD 74 ( milatuzumab ) and anti-CD 20 ( rituximab ) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

  2011cites this paper
• FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

  2010cites this paper
• Cancer esearch apeutics , Targets , and Chemical Biology ponses in Mantle Cell Lymphoma Cells to SNS-032 R end on the Biological Context of Each Cell Line

  2010cites this paper
• Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs

  2010cites this paper
• FTY 720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D 1 and Phospho-Akt in Mantle Cell Lymphoma

  2010cites this paper
• Susceptibility of mantle cell lymphomas to reovirus oncolysis.

  2010cites this paper
• Multicenter phase II study of bendamustine for relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma

  2010cites this paper
• Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

  2010cites this paper
• Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

  2009cites this paper
• Phosphatidylinositol 3′-Kinase Catalytic Subunit α Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma

  2009cites this paper
• Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

  2008cites this paper
• A Severe Combined Immunodeficient–hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma

  2008cites this paper
• Mature B-Cell Neoplasms

  2008cites this paper
• Исследование противоопухолевого механизма действия бетулиновой кислоты и ее производных in vitro

  2008cites this paper
• FACTORES PRONÓSTICOS BIOLÓGICOS Y CLÍNICOS EN EL LINFOMA DE CÉLULAS DEL MANTO

  2008cites this paper
• Mantle cell lymphoma: an overview of diagnostic and therapeutic advances

  2008cites this paper
• Factores pronósticos biológicos y clínicos en el linfoma de células del manto

  2008cites this paper
• Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

  2008cites this paper
• Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

  2008cites this paper
• Adopting Molecular Tools for Diagnosis and Monitoring Malignant Hematological Disease

  2007cites this paper
• Development of a murine model for blastoid variant mantle-cell lymphoma.

  2007cites this paper
• The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA

  2007cites this paper
• A 68-year-old man with multiple colonic polyps discovered upon routine colonoscopy

  2007cites this paper
• Successful Treatment of Focal Segmental Glomerulosclerosis in Association with Mantle Cell Lymphoma

  2007cites this paper
• Defining the role of mTOR in cancer.

  2007cites this paper
• Regulation of transcription and analysis of drug targets in lymphoma and myeloma cells

  2006cites this paper
• Assessing the consequences of hurricane-induced fragmentation of mangrove forest on habitat and nekton in Big Sable Creek, Florida

  2006cites this paper
• Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways.

  2006cites this paper
• mTOR and cancer: insights into a complex relationship

  2006cites this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cites this paper
• Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.

  2006cites this paper